List of Excipients in Branded Drug ATOMOXETINE

Company	Tradename	Ingredient	NDC	Excipient	Potential Generic Entry
Prasco Laboratories	ATOMOXETINE	atomoxetine hydrochloride	66993-040	DIMETHICONE
Prasco Laboratories	ATOMOXETINE	atomoxetine hydrochloride	66993-040	GELATIN
Prasco Laboratories	ATOMOXETINE	atomoxetine hydrochloride	66993-040	SODIUM LAURYL SULFATE
Prasco Laboratories	ATOMOXETINE	atomoxetine hydrochloride	66993-040	STARCH, CORN

Generic Drugs Containing ATOMOXETINE

Company	Ingredient	NDC	Excipient
Teva Pharmaceuticals USA Inc	atomoxetine	0093-3542	AMMONIA
Teva Pharmaceuticals USA Inc	atomoxetine	0093-3542	FERROSOFERRIC OXIDE
Teva Pharmaceuticals USA Inc	atomoxetine	0093-3542	GELATIN
Teva Pharmaceuticals USA Inc	atomoxetine	0093-3542	POTASSIUM HYDROXIDE

What are the Most Frequently-Used Excipients in ATOMOXETINE?

# Of NDCs	Excipient
1	ACID RED 51
11	ALCOHOL
18	AMMONIA
1	BLUE 1

Atomoxetine Excipient Strategy and Commercial Opportunities

Last updated: September 4, 2026

Atomoxetine is a mature, genericized ADHD medicine with limited remaining composition-of-matter protection in the United States. Commercial value now depends on formulation differentiation, pediatric usability, supply reliability, and geographic expansion rather than conventional patent exclusivity.

The strongest opportunities are pediatric oral liquids, orally disintegrating tablets, sprinkle-compatible capsules, lower-cost global products, and formulations that improve swallowing, taste, dose flexibility, or adherence. The principal technical constraints are atomoxetine hydrochloride’s bitter taste, high dose range, capsule-fill economics, moisture control, and the need to preserve rapid and predictable absorption.

What is the FDA status of atomoxetine?

Atomoxetine is a selective norepinephrine reuptake inhibitor approved for attention-deficit/hyperactivity disorder. The reference product is Strattera, originally developed and marketed by Eli Lilly. FDA approved atomoxetine capsules in 2002, and the product received United States pediatric exclusivity in 2008.[1,2]

Atomoxetine is a small-molecule drug, not a biologic. Biosimilar competition is therefore not relevant. Generic applicants use the abbreviated new drug application pathway and must demonstrate pharmaceutical equivalence and bioequivalence to the listed reference drug.

FDA-approved dosage forms and strengths

The principal U.S. dosage form is the immediate-release hard gelatin capsule. Listed strengths include:

Strength	Typical commercial use
10 mg	Initial and low-dose pediatric therapy
18 mg	Pediatric titration
25 mg	Pediatric and adult titration
40 mg	Common maintenance strength
60 mg	Common maintenance strength
80 mg	High-dose maintenance
100 mg	Maximum labeled daily strength

The product is administered once or twice daily. The FDA label permits dosing with or without food and warns against opening capsules because atomoxetine can irritate the eyes.[1]

Atomoxetine is metabolized primarily through CYP2D6. Poor metabolizers and patients receiving strong CYP2D6 inhibitors may have materially higher exposure, which increases the commercial value of flexible, lower-dose presentations and titration-friendly packaging.[1]

What excipients are used in atomoxetine capsules?

The reference capsule relies on a conventional immediate-release excipient system. The FDA label identifies pregelatinized starch, sodium lauryl sulfate, and capsule-shell components among the inactive ingredients.[1]

A generic formulation does not need to duplicate every excipient. It must match the reference product’s dosage form, strength, route, release characteristics, and bioequivalence profile. The formulation must also comply with FDA inactive-ingredient requirements and applicable safety limits.

Functional role of the core excipients

Excipient class	Likely function in atomoxetine capsules	Commercial and technical considerations
Pregelatinized starch	Filler, binder, and disintegration aid	Low cost, established regulatory history, useful for robust capsule fill
Sodium lauryl sulfate	Wetting and dissolution aid	Can improve wetting but may raise irritation and compatibility concerns
Gelatin or HPMC capsule shell	Encapsulation and product presentation	HPMC supports vegetarian and moisture-sensitive positioning
Colloidal silicon dioxide	Flow aid	Supports high-speed filling and content uniformity
Magnesium stearate	Lubricant	Excess levels can slow wetting or dissolution
Microcrystalline cellulose	Filler and carrier	Useful for direct blending and capsule-fill control
Crospovidone or croscarmellose sodium	Disintegration aid	More relevant to tablet and ODT platforms
Film-coating polymers	Color, opacity, handling, and branding	Can improve swallowability and product identification

The key formulation objective is not maximum solubility. Atomoxetine hydrochloride is sufficiently soluble for immediate-release oral delivery, so the development problem is usually control of wetting, powder flow, disintegration, taste, and dose uniformity.

How should manufacturers design an atomoxetine excipient strategy?

The best strategy is a platform approach using a common blend and a limited number of strength-specific adjustments. This reduces manufacturing complexity across 10 mg through 100 mg products.

Capsule platform

A standard hard-capsule formulation can use atomoxetine hydrochloride with pregelatinized starch or microcrystalline cellulose, a glidant, a lubricant, and a wetting agent. Development priorities include:

1. Uniform low-dose distribution, particularly at 10 mg and 18 mg.
2. Consistent capsule fill weight across the strength range.
3. Rapid disintegration and dissolution.
4. Low dust generation during filling.
5. Protection from humidity and electrostatic segregation.
6. Compatibility with high-speed capsule equipment.

Low-dose products often present the highest content-uniformity risk because the API represents a small fraction of total blend weight. Ordered mixing, geometric dilution, or engineered API granules may improve performance. A direct-blend process is commercially attractive, but granulation may provide better flow and segregation control.

Tablet and orally disintegrating tablet platform

An ODT can create a differentiated product, but its value depends on taste masking. Atomoxetine’s bitterness can become more apparent when the dosage form dissolves in the mouth.

Possible approaches include:

• Polymer-coated API particles.
• Ion-exchange resin complexes.
• Lipid or wax-based taste-masking matrices.
• Effervescent or rapidly dispersing systems.
• Sweetener and flavor systems.
• Multiparticulate ODTs containing coated drug particles.

The formulation must avoid delaying atomoxetine release or producing excessive variability between fed and fasted conditions. A taste-masked ODT may require a new clinical bridging strategy if the release profile or exposure differs materially from the approved capsule.

Oral liquid platform

An oral solution or suspension would address children who cannot swallow capsules and would create a meaningful product distinction. The principal challenges are taste, chemical stability, microbial control, dosing accuracy, and packaging.

An oral solution is technically simpler for dose uniformity but exposes the bitter API continuously in the mouth. A suspension can reduce dissolved drug concentration and improve palatability, but it requires control of particle size, redispersibility, sedimentation, viscosity, and dose withdrawal accuracy.

Relevant excipient categories include:

Formulation need	Candidate excipient categories
Sweetness	Sucrose, sorbitol, sucralose, or other approved sweeteners
Flavor	Fruit or berry flavors compatible with pediatric use
Suspending system	Xanthan gum, cellulose derivatives, or similar polymers
Wetting	Polysorbates or other suitable surfactants
Buffering	Citrate, phosphate, or other pH-control systems
Preservation	Approved antimicrobial preservatives where required
Oxidation control	Antioxidants or oxygen-reduced packaging where justified
Packaging	Oral syringe, child-resistant bottle, and light- or moisture-protective closure

The oral liquid opportunity is strongest where pediatric diagnosis and treatment rates are increasing but capsule swallowing remains a barrier. A manufacturer should also evaluate unit-dose cups or sachets for schools, clinics, and adherence programs.

What formulation patents protect atomoxetine products?

Atomoxetine’s core pharmaceutical patent estate is largely expired in major markets. The original protection covered the active compound and related therapeutic use. United States chemical and product protection no longer provides a durable barrier to ordinary generic capsules.

The relevant U.S. exclusivity history is summarized below:

Protection	Product or right	Approximate status
Original compound protection	Atomoxetine and related chemistry	Expired
FDA new chemical entity exclusivity	Strattera	Expired
Pediatric exclusivity	Strattera	Expired
Reference-product capsule protection	Immediate-release atomoxetine	Expired or no longer commercially blocking for standard generics
Later formulation protection	Potential liquid, ODT, modified-release, or taste-masked claims	Must be assessed patent by patent

Patent risk now concentrates on later-developed formulations, manufacturing processes, crystalline forms, delivery systems, and method-of-use claims. The commercial significance of those patents depends on claim scope, enforceability, Orange Book listing, and whether a generic product practices the claimed invention.

Orange Book status

The Orange Book records FDA-approved drug products, patents submitted by sponsors, and applicable exclusivity information. Atomoxetine reference-product listings should be checked against the current FDA Orange Book rather than relying on historical patent summaries.[3]

A standard generic capsule generally faces lower patent risk than a product designed to copy a later patented liquid, ODT, sprinkle, or modified-release platform. A formulation sponsor should conduct a claim chart against:

• Composition claims covering atomoxetine and specific excipient ratios.
• Coated-particle and taste-masking claims.
• Oral liquid stability claims.
• Multiparticulate and sprinkle formulations.
• Modified-release delivery systems.
• Manufacturing claims involving granulation, drying, or particle engineering.
• Method-of-use claims directed to ADHD subpopulations or dosing schedules.

When did atomoxetine lose exclusivity?

Atomoxetine lost the commercial protection associated with its original approval after expiration of the applicable chemical patent, FDA exclusivity, and pediatric extension. FDA approved generic atomoxetine products in the 2010s, and multiple manufacturers now compete in the market.[2,4]

The practical timeline is:

Milestone	Approximate timing
FDA approval of Strattera	2002
U.S. pediatric exclusivity period	Extended reference-product protection into approximately 2011
Generic development and approvals	Primarily during the 2010s
Current U.S. market	Multi-source generic competition

Because atomoxetine is a small molecule with established bioequivalence precedent, a conventional capsule applicant does not need to establish clinical efficacy through a new Phase 3 program. The regulatory burden is materially lower than for a new chemical entity, but a differentiated dosage form may require more extensive development.

Which companies compete in the atomoxetine market?

Competition includes Eli Lilly’s reference product and generic manufacturers that have obtained FDA approval for one or more capsule strengths. Public databases identify products from companies such as Teva, Apotex, Aurobindo, Dr. Reddy’s, Rising Pharmaceuticals, Amneal, and other approved suppliers, depending on strength and market period.[4]

The competitive field is fragmented. No single company necessarily has durable control across all strengths, wholesalers, retail channels, and institutional accounts. This creates opportunities in:

• Reliable supply of all major strengths.
• Shortage-resilient manufacturing.
• Private-label and contract manufacturing.
• Pediatric-friendly dosage forms.
• Non-U.S. markets where branded products remain expensive.
• Combination packaging that supports titration.
• Alternate capsule-shell positioning, including HPMC.

How does atomoxetine compare with competing ADHD drugs?

Product	Drug class	Main dosage-form opportunity	Competitive constraint
Atomoxetine	Nonstimulant selective norepinephrine reuptake inhibitor	Pediatric liquid, ODT, sprinkle, flexible titration	Generic capsule pricing
Methylphenidate	Stimulant	Extended release, transdermal, liquid, chewable	Controlled-substance regulation
Amphetamine products	Stimulant	Extended release, liquid, chewable, ODT	Controlled-substance regulation
Guanfacine	Nonstimulant alpha-2A agonist	Extended-release tablet, pediatric positioning	Sedation and once-daily competition
Clonidine	Nonstimulant alpha-2 agonist	Extended-release tablet	Blood-pressure and sedation considerations

Atomoxetine has a commercial advantage where prescribers seek a nonstimulant option or where stimulant diversion and controlled-substance handling are concerns. Its disadvantages include slower onset than stimulants, gastrointestinal effects, somnolence in some patients, and dose titration requirements.[1]

What generic entry risks exist for atomoxetine?

The standard generic capsule has relatively low regulatory and patent risk because the market is already multisource. Higher-risk opportunities include products that depart from the reference presentation.

Main risk categories

1. Bioequivalence risk. Taste-masked particles, suspensions, and ODTs can change dissolution and absorption.
2. Pediatric usability risk. A product that is difficult to measure, swallow, or tolerate will have weak commercial uptake.
3. Stability risk. Liquid products may face hydrolysis, oxidation, microbial growth, or preservative loss.
4. IP risk. A novel formulation may fall within an active patent even if the active ingredient is unprotected.
5. Manufacturing risk. Low-dose blends can fail content uniformity or generate segregation during transport.
6. Pricing risk. A differentiated product must justify a premium over inexpensive capsules.
7. Labeling risk. Capsule-opening restrictions create a practical barrier to sprinkle or food-mixing claims.

Which atomoxetine formulations offer the strongest commercial opportunities?

Pediatric oral liquid

This is the clearest unmet-use-case opportunity. The product can target young children, patients with swallowing difficulties, and caregivers who need dose flexibility. A suspension may offer the best balance between dose accuracy and taste management, but the product requires robust shake instructions and an oral syringe.

Orally disintegrating tablet

An ODT could improve portability and swallowing. Its success depends on effective taste masking without delaying release. It is most attractive in strengths used for titration, including 10 mg, 18 mg, 25 mg, and 40 mg.

Sprinkle-compatible multiparticulates

A sprinkle product could be administered with soft food, but atomoxetine’s capsule label restrictions mean that a new product should not rely on informal capsule-opening practices. A purpose-built multiparticulate dosage form could capture patients who cannot swallow capsules while preserving solid-dose stability.

Titration and adherence packs

Atomoxetine often requires gradual dose adjustment. A calendar package containing multiple strengths could improve initiation and reduce dispensing friction. The pack itself may not create patent exclusivity, but it can support payer, pharmacy, and prescriber differentiation.

Global low-cost supply

Outside the United States, regulatory requirements, brand penetration, and local manufacturing economics vary. Opportunities are strongest where:

• The reference product remains priced at a premium.
• Generic registration is available through a reliance or abridged pathway.
• Pediatric dosing flexibility is limited.
• Local production receives procurement preference.
• Capsule supply is inconsistent.

How strong is the atomoxetine patent estate?

The patent estate is weak for ordinary immediate-release capsules and stronger only where a later patent claims a specific delivery technology. Investors and licensees should distinguish between expired compound patents, abandoned applications, unlisted formulation patents, and enforceable issued claims.

A practical strength assessment is:

Asset type	Relative strength
Atomoxetine active ingredient	Low, expired
Conventional immediate-release capsule	Low
Standard excipient substitution	Low to moderate
Taste-masked API particles	Moderate, claim dependent
Oral liquid stability system	Moderate, claim dependent
ODT with defined disintegration and taste profile	Moderate
Modified-release product	Potentially higher, but development and clinical risk is higher
Manufacturing process	Moderate if difficult to design around and supported by strong process data

The best protection strategy combines formulation claims with manufacturing claims, stability specifications, particle attributes, and carefully drafted use claims. A patent that covers only a routine excipient substitution will face design-around pressure and may have limited licensing value.

What licensing and partnership opportunities exist?

Atomoxetine is suitable for asset-light partnerships because the API and conventional capsule technology are mature. Potential deal structures include:

• Regional commercialization licenses for pediatric liquids or ODTs.
• Contract development and manufacturing agreements.
• Private-label supply for pharmacy and hospital channels.
• Co-development of taste-masked multiparticulates.
• Technology licenses for particle coating or microencapsulation.
• Local registration partnerships in emerging markets.
• Portfolio deals combining atomoxetine with other ADHD products.

The most valuable licensable asset is likely a validated pediatric delivery platform that can be reused across several bitter ADHD medicines. A single atomoxetine capsule product has limited licensing leverage unless it offers reliable supply, a differentiated regulatory status, or access to a protected geography.

What is the likely revenue exposure from atomoxetine?

Revenue exposure is concentrated in generic volume rather than durable brand pricing. Standard capsules face aggressive price competition, tender pressure, and pharmacy substitution. A differentiated liquid, ODT, or sprinkle product can command a higher net price if it demonstrates practical benefit and avoids direct substitution.

Commercial forecasts should separate:

• Reference-brand revenue.
• Commodity generic revenue.
• Premium pediatric-formulation revenue.
• Institutional and tender revenue.
• Contract-manufacturing revenue.
• Geographic markets with limited generic penetration.

A pediatric formulation can produce better margins than a standard capsule, but its total addressable market is smaller. The strongest business case usually combines a low-cost capsule portfolio with one differentiated pediatric product.

Key Takeaways

• Atomoxetine is an FDA-approved nonstimulant ADHD drug with extensive generic competition.
• Original compound and exclusivity protections have expired in the United States.
• Conventional immediate-release capsules have limited patent and pricing power.
• The strongest excipient opportunities involve taste masking, dose uniformity, disintegration, liquid stability, and pediatric acceptability.
• Oral suspensions, oral solutions, ODTs, and purpose-built sprinkle formulations offer the clearest differentiation.
• Atomoxetine is not eligible for biosimilar competition because it is a small molecule.
• Formulation patents may still matter, particularly for taste-masked particles, liquid systems, modified release, and multiparticulates.
• A platform-based pediatric formulation can have more licensing value than a standalone generic capsule.
• Commercial success depends on regulatory simplicity, reliable supply, and a demonstrable usability advantage over low-cost capsules.

FAQs

Is atomoxetine a controlled substance?

No. Atomoxetine is a nonstimulant ADHD medicine and is not federally scheduled as a controlled substance in the United States.[1]

Can atomoxetine capsules be opened and mixed with food?

The FDA label instructs patients not to open atomoxetine capsules because the powder can irritate the eyes. A food-mixing product should use a specifically developed and labeled formulation rather than relying on capsule manipulation.[1]

Does atomoxetine need a taste-masking formulation?

A taste-masking approach is most valuable for oral liquids, suspensions, ODTs, and multiparticulates. Conventional intact capsules generally avoid meaningful taste exposure.

Could a new atomoxetine liquid receive three-year FDA exclusivity?

A qualified new formulation may receive regulatory exclusivity if it contains a new clinical investigation essential to approval and satisfies statutory requirements. The availability and duration depend on the specific 505(b)(2) or other regulatory pathway and the supporting clinical work.[5]

Is a modified-release atomoxetine product commercially attractive?

Potentially, but the development burden is higher than for a standard capsule. The product would need to show a meaningful dosing or tolerability benefit against inexpensive immediate-release generics and address formulation, pharmacokinetic, and patent risks.

References

1. U.S. Food and Drug Administration. (2023). Strattera (atomoxetine hydrochloride) prescribing information.
2. U.S. Food and Drug Administration. (2008). FDA approves pediatric exclusivity for Strattera.
3. U.S. Food and Drug Administration. (2024). Approved drug products with therapeutic equivalence evaluations: Orange Book.
4. U.S. Food and Drug Administration. (2024). Drugs@FDA: FDA-approved drugs database, atomoxetine products.
5. U.S. Food and Drug Administration. (2019). Guidance for industry: Applications covered by section 505(b)(2).